Novo Nordisk CEO Mike Doustdar said weight-loss pills could account for as much as half of the global obesity-drug market by 2030, positioning the Danish drugmaker for a potentially faster shift away from weekly injections than Wall Street forecasts anticipate. Novo has five oral treatments in development and launched the first obesity pill earlier this year ahead of rival Eli Lilly. Oral therapies represented about one-third of US obesity prescriptions after the Wegovy pill rollout, while Novo captured more than 80% of new oral prescriptions and recorded nearly DKK 5.5 billion ($843 million) in first-half pill sales. The company is also seeking growth beyond Ozempic and Wegovy, which generate roughly 75% of revenue and face patent expirations in major markets in the early 2030s. Novo aims to launch more than five blockbuster medicines by 2030 and add over $23 billion in revenue by 2035, while considering acquisitions and partnerships in cardiovascular disease and other areas complementary to obesity treatment.